Preliminary reports have explored the addition of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, to NAC regimens to enhance tumor response through angiogenesis inhibition and improve oncological outcomes [16-18]. This evidence concerns the gene VEGFA and neoplasm.